Brought to you by 
Regeneron and Intellia enter six-year CRISPR/Cas9 agreement; deal expanded
27 Jan 2023
Executive Summary
Under a six-year agreement, Regeneron Pharmaceuticals Inc. and Intellia Therapeutics Inc. will work together to advance Intellia's CRISPR/Cas9 gene editing technology for in vivo therapeutic use.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
-
Drug Discovery Technologies
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Regeneron and Intellia enter six-year CRISPR/Cas9 agreement; deal expanded
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice